| scholarly article | Q13442814 |
| P2093 | author name string | Andersen JR | |
| Hansen TM | |||
| Helleberg L | |||
| Jess P | |||
| Malchow-Møller A | |||
| Manniche C | |||
| Nielsen SE | |||
| Pedersen C | |||
| Rasmussen SN | |||
| Tage-Jensen U | |||
| P2860 | cites work | Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease | Q28266979 |
| Cimetidine for peptic ulcer in patients with arthritis | Q33552538 | ||
| Non-steroidal anti-inflammatory drugs and peptic ulcer perforation | Q34526085 | ||
| Upper gastrointestinal disease in rheumatoid arthritis | Q34700265 | ||
| Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer | Q40094736 | ||
| Incidence of Gastric Lesions in Patients with Rheumatic Disease on Chronic Aspirin Therapy | Q40722738 | ||
| Inadequacy of the literature on the relationship between drugs, ulcers, and gastrointestinal bleeding. | Q52725958 | ||
| Ranitidine: A New H2-Receptor Antagonist | Q54487188 | ||
| Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up. | Q54509942 | ||
| Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer | Q69877679 | ||
| Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents | Q70577956 | ||
| Gastroscopic evaluation of anti-inflammatory agents | Q71131818 | ||
| Placebos in clinical trials of duodenal ulcer: the end of an era? | Q71360619 | ||
| Reappraisal of the effects of aspirin on the stomach | Q72429131 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| patient | Q181600 | ||
| rheumatism | Q684924 | ||
| P304 | page(s) | 226-229 | |
| P577 | publication date | 1987-02-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease | |
| P478 | volume | 28 |
| Q34408418 | Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs |
| Q45058341 | Curative and preventive treatment of NSAID-associated gastroduodenal ulcers |
| Q28335522 | Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers |
| Q40661010 | Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs |
| Q38254644 | Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies |
| Q73864418 | Evidence for participation of gliostatin/platelet-derived endothelial cell growth factor in gastric ulcer healing |
| Q36660294 | Gastric cytoprotection. What does it really mean for the prescriber? |
| Q38611803 | Gastroduodenal effects of nonsteroidal antiinflammatory drugs |
| Q32065086 | Healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions, and relief of dyspeptic symptoms: a commentary on the new data |
| Q38353541 | Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease |
| Q28201393 | Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? |
| Q35705841 | Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit |
| Q35920722 | Management of gastroduodenopathy associated with use of nonsteroidal anti-inflammatory drugs |
| Q37785035 | Mechanisms of NSAID-induced gastroenteropathy |
| Q36911181 | Misoprostol--a logical therapeutic approach to gastroduodenal mucosal injury induced by non-steroidal anti-inflammatory drugs? |
| Q43206510 | NSAIDs--should every prescription carry a government health warning? |
| Q36517019 | Non-steroidal anti-inflammatory drug-induced gastroduodenal injury: therapeutic recommendations |
| Q38627221 | Non-steroidal anti-inflammatory drug-induced gastropathy. Mechanisms and management |
| Q38678828 | Non-steroidal anti-inflammatory drugs and the gastrointestinal tract |
| Q35707355 | Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit |
| Q35707627 | Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: to be considered in certain circumstances |
| Q71523193 | Nonsteroidal anti-inflammatory drug gastropathy |
| Q41078785 | Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury |
| Q40567516 | Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword |
| Q24203871 | Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity |
| Q45818251 | Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin |
| Q33678334 | Prophylaxis and treatment of NSAID-induced gastroduodenal disorders |
| Q34517173 | Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects |
| Q34393522 | Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers |
| Q43492439 | Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy |
| Q38672468 | Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases |
| Q40816610 | Rheumatoid arthritis in the aged. Incidence and optimal management |
| Q34409898 | Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy |
| Q57386566 | Side-effects of non-steroidal anti-inflammatory drugs |
| Q34392497 | Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study |
| Q44779582 | The Management of Non-Steroidal Anti-Inflammatory Drug-Induced Gastroduodenal Ulcers |
| Q37717322 | The management of NSAID gastropathy |
| Q38297809 | The role of prostaglandins in gastric mucosal protection |
| Q34561025 | Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. |
| Q37230285 | Treatment and chemoprevention of NSAID-associated gastrointestinal complications. |
| Q39498178 | Treatment of nonsteroidal antiinflammatory drug-induced gastric ulcers with misoprostol. A double-blind multicenter study |
| Q38709591 | Treatment of peptic ulcer disease in the arthritic patient |
| Q67979617 | [Epidemiology and treatment of gastroduodenal lesions caused by non-steroidal anti-inflammatory agents] |
Search more.